Stereotactic ablative radiation against metastatic lesion detected by DWIBS for High risk Prostate Cancer
Not Applicable
Recruiting
- Conditions
- Prostate cancer
- Registration Number
- JPRN-UMIN000044546
- Lead Sponsor
- Mie University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Male
- Target Recruitment
- 10
Inclusion Criteria
Not provided
Exclusion Criteria
1) History of any prostate cancer therapy 2) Severe heart disease (NYHA criteria>=class 3) 3) Cerebral vascular disease with higher cerebral dysfunction 4) Liver disease (total bilirubin> 3*ULN OR ALT/AST>5* ULN) 5) Uncontrollable diabetes mellitus (HbA1c >8.0%) 6) Contraindication for MRI 7) Patient who is considered ineligible for enrolling the study by a principal investigator or sub-investigator
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 3-year composite disease progression free survival rate
- Secondary Outcome Measures
Name Time Method progression-free survival the rate of adverse events QOL recurrence rate of metastatic lesion with SBRT detection rate of DWIBS time to CRPC time to new metastatic lesion rate of hormonal therapy 36-months after protocol therapy rate of metastatic-directed therapy Analysis of survival and other clinical parameters with historical control of high risk prostate cancer using propensity-score matching method